CAJ | 학술논문

目的：研究瑞舒伐他汀对冠心病患者血浆泛癸利酮浓度的影响及临床合理应用。方法筛选符合要求的35例冠心病住院患者，每晚8时给予瑞舒伐他汀钙片10 mg，连续服用12周，分别于服药前、服药4周末、服药12周末测量血浆泛癸利酮浓度、血脂、血糖、肝功能、肾功能，分析服药前、服药4周、服药12周血浆泛癸利酮的浓度与降脂疗效、安全性的相关性，并进行数据统计。结果服药4周、12周与服药前相比血浆泛癸利酮浓度下降42．11％、63．16％，差异有统计学意义（P＜0．01），服药4周末与服药12周末相比，差异有统计学意义（P＜0．05）；服药4周末、12周末与服药前相比血清总胆固醇（TC）分别下降，差异有统计学意义（P＜0．01），服药4周末与服药12周末相比，差异无统计学意义（P＞0．05）；服药4周末、12周末与用药前相比血清低密度脂蛋白胆固醇（LDL-C）分别下降，差异有统计学意义（P＜0．01）；服药4周与服药12周相比LDL-C的差异无统计学意义（P＞0．05）；高密度脂蛋白胆固醇（HDL-C）、甘油三酯（TG）、丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、血尿素氮（BUN）、血肌酐（Cr）、肌酸激酶（CK）、空腹血糖（FBG）服药4周末、12周末与服药前相比差异无统计学意义（P＞0．05）；35例患者服用瑞舒伐他汀12周内未观察到全身性的药物不良事件、检测指标的异常及心血管不良事件。结论常规剂量瑞舒伐他汀能够显著降低血浆泛癸利酮浓度，有效地降低TC、LDL-C水平，血浆泛癸利酮浓度的降低与LDL-C水平有部分相关性，且其安全性好。
목적：연구서서벌타정대관심병환자혈장범계리동농도적영향급림상합리응용。방법사선부합요구적35례관심병주원환자，매만8시급여서서벌타정개편10 mg，련속복용12주，분별우복약전、복약4주말、복약12주말측량혈장범계리동농도、혈지、혈당、간공능、신공능，분석복약전、복약4주、복약12주혈장범계리동적농도여강지료효、안전성적상관성，병진행수거통계。결과복약4주、12주여복약전상비혈장범계리동농도하강42．11％、63．16％，차이유통계학의의（P＜0．01），복약4주말여복약12주말상비，차이유통계학의의（P＜0．05）；복약4주말、12주말여복약전상비혈청총담고순（TC）분별하강，차이유통계학의의（P＜0．01），복약4주말여복약12주말상비，차이무통계학의의（P＞0．05）；복약4주말、12주말여용약전상비혈청저밀도지단백담고순（LDL-C）분별하강，차이유통계학의의（P＜0．01）；복약4주여복약12주상비LDL-C적차이무통계학의의（P＞0．05）；고밀도지단백담고순（HDL-C）、감유삼지（TG）、병안산전안매（ALT）、천동안산전안매（AST）、혈뇨소담（BUN）、혈기항（Cr）、기산격매（CK）、공복혈당（FBG）복약4주말、12주말여복약전상비차이무통계학의의（P＞0．05）；35례환자복용서서벌타정12주내미관찰도전신성적약물불량사건、검측지표적이상급심혈관불량사건。결론상규제량서서벌타정능구현저강저혈장범계리동농도，유효지강저TC、LDL-C수평，혈장범계리동농도적강저여LDL-C수평유부분상관성，차기안전성호。
Objective To investigate the effects and of Rosuvastatin on the concentration of plasma ubide-carenone and its rationality of clinical use in patients with coronary heart disease. Methods Thirty-five hospitalized patients with coronary heart disease who fulfilled the inclusion criteria were recruited and given 10 mg rosuvastatin calcium tablet at 8 pm every evening for continuous 12 weeks. The plasma ubidecarenone concentration, blood lipids, blood glucose, liver and renal functions were measured respectively before the medication, and at the end of four and twelve weeks after the medication. The correlations among plasma Ubidecarenone concentration, lipid-lowering effica-cy and safety before the medication, four weeks and twelve weeks after the medication were statistical analyzed. Re-sults Plasma Ubidecarenone concentration after 4 weeks and 12 weeks of medication decreased by 42.11% and 63.16%, respectively, compared with those before the medication (P<0.01). Also, statistical difference was found in plasma Ubidecarenone between 4 and 12 weeks after medication (P<0.05). At the end of the four and twelve weeks of medication, the serum total cholesterol (TC) decreased by 29.14% and 35.01%, respectively, compared with before medication (P<0.01). However, no statistical significance was found between TC level at the end of the fourth and the twelfth weeks (P>0.05). At the end of these two time points, the serum low density lipoprotein cholesterol (LDL-C) de-creased by 28.34%and 36.44%, respectively, compared with before medication ( P<0.01). The LDL-C levels at the end of the fourth and the twelfth weeks did not differ statistically (P>0.05). The high density lipoprotein cholesterol (HDL-C), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), serum creatinine (Cr), creatine kinase (CK), fasting blood glucose (FBG) at the end of the fourth and the twelfth weeks did not show any change from those before the medication (P>0.05). No systemic drug-related adverse events were ob-served in 35 patients on the 12-week treatment with Rosuvastatin. Conclusion Routine dose of rosuvastatin may sig-nificantly decrease the plasma ubidecarenone concentration, and effectively reduce TC and LDL-C levels. The de-crease in plasma ubidecarenone is concentration partially correlated with the LDL-C level. In addition, plasma ubide-carenone is with good safety profiles.